M A Taffe1. 1. Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. mtaffe@scripps.edu
Abstract
BACKGROUND: Cannabis is commonly consumed by Ecstasy (3,4-methylenedioxymethamphetamine; MDMA) users, including as an intentional strategy to manipulate the drug experience. The most active psychoactive constituent in cannabis, Δ(9)-tetrahydrocannabinol (THC), and other drugs with partial or full agonist activity at the CB(1) receptor, produces a reduction of body temperature in rodents. Reports show that administration of THC can attenuate temperature increases caused by MDMA in mice or rats; however, a recent study in humans shows that THC potentiates MDMA-induced temperature elevations. Relatively little scientific evidence on the thermoregulatory effects of THC in monkeys is available. METHODS: The body temperature of male rhesus macaques was recorded after challenge with THC (0.1-0.3 mg/kg, i.m.) or combined challenge of THC with the CB(1) receptor antagonist SR141716 (Rimonabant; 0.3 mg/kg, i.m.) or combined challenge of THC (0.1, 0.3 mg/kg, i.m.) with MDMA (1.78 mg/kg p.o.) using minimally-invasive, implanted radiotelemetry techniques. RESULTS: THC reduced the body temperature of monkeys in a dose-dependent manner with the nadir observed 3-5 h post-injection; however, an attenuation of normal circadian cooling was also produced overnight following dosing. Hypothermia induced by THC (0.3 mg/kg, i.m.) was prevented by Rimonabant (0.3 mg/kg, i.m.). Finally, 0.3 mg/kg THC (i.m.) attenuated the elevation of body temperature produced by MDMA for about 4 h after oral dosing. CONCLUSIONS: As with rodents THC produces a robust and lasting decrement in the body temperature of rhesus monkeys; this effect is mediated by the CB(1) receptor. THC also protects against the immediate hyperthermic effects of MDMA in monkeys in a dose-dependent manner. Nevertheless, a paradoxical attenuation of circadian cooling overnight after the THC/MDMA combination cautions that longer-term effects may be critical in assessing risks for the recreational user of cannabis in combination with MDMA.
BACKGROUND: Cannabis is commonly consumed by Ecstasy (3,4-methylenedioxymethamphetamine; MDMA) users, including as an intentional strategy to manipulate the drug experience. The most active psychoactive constituent in cannabis, Δ(9)-tetrahydrocannabinol (THC), and other drugs with partial or full agonist activity at the CB(1) receptor, produces a reduction of body temperature in rodents. Reports show that administration of THC can attenuate temperature increases caused by MDMA in mice or rats; however, a recent study in humans shows that THC potentiates MDMA-induced temperature elevations. Relatively little scientific evidence on the thermoregulatory effects of THC in monkeys is available. METHODS: The body temperature of male rhesus macaques was recorded after challenge with THC (0.1-0.3 mg/kg, i.m.) or combined challenge of THC with the CB(1) receptor antagonist SR141716 (Rimonabant; 0.3 mg/kg, i.m.) or combined challenge of THC (0.1, 0.3 mg/kg, i.m.) with MDMA (1.78 mg/kg p.o.) using minimally-invasive, implanted radiotelemetry techniques. RESULTS:THC reduced the body temperature of monkeys in a dose-dependent manner with the nadir observed 3-5 h post-injection; however, an attenuation of normal circadian cooling was also produced overnight following dosing. Hypothermia induced by THC (0.3 mg/kg, i.m.) was prevented by Rimonabant (0.3 mg/kg, i.m.). Finally, 0.3 mg/kg THC (i.m.) attenuated the elevation of body temperature produced by MDMA for about 4 h after oral dosing. CONCLUSIONS: As with rodents THC produces a robust and lasting decrement in the body temperature of rhesus monkeys; this effect is mediated by the CB(1) receptor. THC also protects against the immediate hyperthermic effects of MDMA in monkeys in a dose-dependent manner. Nevertheless, a paradoxical attenuation of circadian cooling overnight after the THC/MDMA combination cautions that longer-term effects may be critical in assessing risks for the recreational user of cannabis in combination with MDMA.
Authors: Wael M Y Mohamed; Sami Ben Hamida; Jean-Christophe Cassel; Anne Pereira de Vasconcelos; Byron C Jones Journal: Pharmacol Biochem Behav Date: 2011-07-05 Impact factor: 3.533
Authors: G J Dumont; C Kramers; F C Sweep; D J Touw; J G van Hasselt; M de Kam; J M van Gerven; J K Buitelaar; R J Verkes Journal: Clin Pharmacol Ther Date: 2009-05-13 Impact factor: 6.875
Authors: G J H Dumont; J G C van Hasselt; M de Kam; J M A van Gerven; D J Touw; J K Buitelaar; R J Verkes Journal: J Psychopharmacol Date: 2010-09-03 Impact factor: 4.153
Authors: Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Tobin J Dickerson; Michael A Taffe Journal: Psychopharmacology (Berl) Date: 2015-05-01 Impact factor: 4.530
Authors: Eugene A Kiyatkin; Suelynn Ren; Ken T Wakabayashi; Michael H Baumann; Yavin Shaham Journal: Neuropsychopharmacology Date: 2015-06-24 Impact factor: 7.853
Authors: Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan Journal: Neuropsychopharmacology Date: 2017-09-06 Impact factor: 7.853
Authors: Jacques D Nguyen; Shawn M Aarde; Sophia A Vandewater; Yanabel Grant; David G Stouffer; Loren H Parsons; Maury Cole; Michael A Taffe Journal: Neuropharmacology Date: 2016-05-30 Impact factor: 5.250
Authors: Brett C Ginsburg; Lenka Hruba; Armia Zaki; Martin A Javors; Lance R McMahon Journal: Drug Alcohol Depend Date: 2014-03-19 Impact factor: 4.492